LLS.ORG (USA) WHAT ARE YOUR TOP PRIORITIES FOR... - CLL Support

CLL Support

22,366 members38,466 posts

LLS.ORG (USA) WHAT ARE YOUR TOP PRIORITIES FOR 2023?

lankisterguy profile image
lankisterguyVolunteer
0 Replies

Dear Advocate,

Whether it’s making sure every patient can afford health insurance that works for them or advancing better treatments, LLS is committed to working tirelessly to advance policies that serve the needs of blood cancer patients and their families.

In 2023 we will continue to work closely with dedicated volunteer advocates, like you, and elevate the voices of patients to state and federal elected officials, the White House, governors and even courts, when it matters most. We are excited to share a few of our top policy priorities for this year and would love to know which are most important to you.

SURVEY: WHAT ARE YOUR TOP PRIORITIES FOR 2023? advocacy.lls.org/a/2023-pri...

In 2023, LLS is committed to ensuring patients have access to high-quality health insurance. Cancer patients should never be blocked from life-saving treatment.

• We are focused on ensuring that Medicaid is available for those who need it, no matter where they live.

• This goal includes preventing or limiting "junk insurance," which provides little coverage and can discriminate against cancer patients.

We’re also prioritizing making cancer care affordable, now and in the future.

• We are working to reduce patients’ out-of-pocket costs for treatment, on an annual and monthly basis.

• This includes helping to protect patients from medical debt and unexpected costs that arise from surprise medical bills

This year, with your help, LLS is continuing to stand up for kids and young adults diagnosed with cancer.

• We want to ensure pediatric patients are able to access time-sensitive cancer care outside of their home state.

• LLS is working to accelerating the development of new treatments for childhood cancer.

Below are some of our other many priorities for 2023

• Increasing state and federal funding for cancer research.

• Removing barriers to clinical trial enrollment.

• Removing health and financial burdens for cancer survivor.

SURVEY: WHAT ARE YOUR 2023 PRIORTIES? advocacy.lls.org/a/2023-pri...

We can’t achieve these goals without your help! We’re excited to continue working together this year. Thank you for all that you do to support cancer patients.

Sincerely, Danielle Bubnis Executive Director, Advocacy The Leukemia and Lymphoma Society

P.S. Want to get these alerts even faster? Join our Mobile Action Network by texting SPEAK to 698-66 (message & data rates may apply).

Authorized and paid for by The Leukemia & Lymphoma Society, 10 G Street NE, Suite 400, Washington, DC, 20002. (202) 969-1800.

3 International Drive, Suite 200 | Rye Brook, NY 10573

lss.org/

The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

3 International Drive, Suite 200 | Rye Brook, NY 10573

lls.org/

-

Len

Written by
lankisterguy profile image
lankisterguy
Volunteer
To view profiles and participate in discussions please or .
Read more about...

You may also like...

Top 10 list of what we need to know about lymphoma

online health advocates blogging and tweeting on HIV and diabetes and arthritis and mental health...

Uk What is the exact SNOMED code for CLL to get priority PCR test kit and letter?

In the continuing saga of trying to get a priority PCR test and letter does anybody know the exact...

Please Help with the Global Leukaemia Patient Experience Survey 2021

the CML Advocates Network (CMLAN) are running a Global Leukemia Patient Experience Survey 2021 to...

Wine! Priority Post. lol

UK Patients: Can you help with your opinion about treatment options. Have you received Ibrutinib + Venetoclax as your first treatment?

evidence of the patient experience of treatments in CLL and specifically, of this treatment for a...